1. Un-audited Financial Results of the Company for the Quarter and Nine Months Ended December 31, 2025. (Copies enclosed herewith). 2. Took note of Limited Review Report of the Statutory ....

Revenue declinedExceptional itemResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.9%Reaction day

₹88.10

prior close

₹88.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+1.4% vs market

Pharmaceuticals peers, median of 157sector-0.7%+1.6% vs sector

On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.1

15m

+0.1

30m

+1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.9-0.5+1.4-0.7+1.6

Next day

-1.0-2.0+1.0-1.4+0.5

+1.0-2.7+3.7-2.1+3.2

+0.5-1.7+2.2-1.6+2.1

-3.4-1.4-2.0-1.6-1.8

-3.5-2.8-0.7-2.4-1.1

-7.4-2.8-4.6-2.9-4.6

15d

-9.1-8.4-0.7-6.3-2.7

-5.8-9.1+3.3-6.6+0.9

+9.0-4.0+13.0-3.5+12.4

+43.1+2.6+40.5+0.7+42.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Godavari Drugs reported weak Q3 FY26 results, with revenue from operations declining about 25% YoY to ₹22.18 crore (vs ₹29.55 crore in Q3 FY25), while net profit was nearly flat at ₹75.76 lakhs vs ₹76.74 lakhs. For the nine months ended December 2025, revenue fell around 17% YoY to ₹72.65 crore and net profit dropped about 20% to ₹2.80 crore (vs ₹3.49 crore). The company reported an exceptional item of ₹25.13 lakhs in the quarter. Separately, the Board approved a short-term working capital term loan of ₹5.50 crore from ICICI Bank for 6 months (bullet repayment) to fund new order execution. The auditor (Ayyadevara & Co.) issued an unqualified Limited Review Report.

Likely market impact

The double-digit revenue and profit decline signals demand or pricing pressure that may weigh on the stock, though the new working capital loan points to upcoming order wins. Short-tenure debt with bullet repayment adds a liquidity event to watch at end of term.